From July 22 to 24, 2026,TONACEA will host The 1st China Pharmaceutical Innovation Conference(CPIC)at the National Exhibition and Convention Center (Shanghai).

 

CPIC will establish a model of “China Innovation – Global Partnerships – Shanghai Dealmaking”.

 

As the premier gateway for international capital to navigate China’s innovation ecosystem, and a strategic hub for Chinese pharmaceutical companies to scale globally, CPIC will undoubtedly set the benchmark for investment and partnership in the healthcare industry.

 

CPIC will feature dozens of specialized sessions covering hot topics and future directions in healthcare innovation investment and globalization.

 

Small nucleic acid drugs are sparking the third wave of modern pharmaceuticals. From rare diseases to chronic conditions, and from intrahepatic targeting to extrahepatic delivery, every technical breakthrough is reshaping the therapeutic landscape.

 

Co-organized by Tofflon, InnoStar, and GemPharmatech, the "Global Meeting on Small Nucleic Acid Drug Innovation" will gather top-tier scientists, industry leaders, and clinical experts. The meeting will focus on core issues such as breakthroughs in delivery technology, CMC process development, non-clinical evaluation, and industrialization, collectively exploring the next decade of the field.

 

From July 22–24, at the National Exhibition and Convention Center (Shanghai), we look forward to joining you at the crest of this small nucleic acid wave.

 

 

About Tofflon

 

Tofflon Science and Technology Group Co., Ltd.（Tofflon）(Stock Code: 300171), founded in 1993 and listed on the ChiNext board in 2011, is a Shanghai-based global provider of integrated solutions for the pharmaceutical industry. The company offers a comprehensive portfolio including process services, consumables, core equipment, and engineering.

 

Guided by its core value of "Heaven Rewards Diligence" and the mission of "Professional Technologies Serving Biomedicine," Tofflon advances through its strategic pillars of Systematization, Internationalization, and Digital Intelligence.

 

Tofflon has four core divisions: Bioprocess, Formulation Equipment, Engineering, and Food Engineering. To date, it has 35 domestic holding subsidiaries (e.g., Tofflon Life Science, Tofflon Dehui) and 17 overseas holding subsidiaries, with 8 manufacturing bases worldwide and 3 global R&D centers in China, the United States, and Germany. Continuously strengthening research in pharmaceutical manufacturing science and pharmaceutical machinery engineering, Tofflon strives to build the “Next-Generation Pharmaceutical Manufacturing Platform,” providing professional solutions for clients in R&D, pilot scale-up, and commercial production, and accelerating drug development and large-scale commercialization.

 

 

About InnoStar

 

Shanghai InnoStar Bio-tech Co., Ltd. (InnoStar)(Stock Code: 688710), was established in 2010.It is a holding subsidiary of China National Pharmaceutical Group Corporation-affiliated China State Institute of Pharmaceutical Industry Co., Ltd.

 

The company is a professional CRO providing comprehensive high-quality R&D services for innovative biopharmaceuticals. It has successively obtained the GLP certification from NMPA, passed GLP inspections by the U.S. FDA, and acquired OECD GLP certification, AAALAC accreditation, as well as CAP certification from the College of American Pathologists.

 

Its business scope covers early druggability evaluation, non-clinical pharmacodynamics, pharmacokinetics, safety evaluation, as well as clinical bioanalytical testing, biomarker research and translational medicine studies.

 

Currently, InnoStar owns modern facilities covering 74,000 square meters and a research team of over 1,000 professionals, mainly based in Shanghai and Nantong, boasting industry-leading international service capabilities.

 

As of December 31, 2025, the company has supported the R&D of global innovative medicines with 35 successful NDA/BLA approvals and over 830 IND registrations. It has assisted more than 150 projects in obtaining clinical trial approvals from overseas regulatory authorities, including 3 FDA NDA/BLA approvals. Additionally, InnoStar has supported the R&D of over 200 domestic and international first-in-class innovative drug programs.

 

 

About GemPharmatech

 

GemPharmatech Co., Ltd. (GemPharmatech)(Stock Code: 688046) is a national high-tech enterprise specializing in the R&D and production of laboratory mouse and rat models, as well as non-clinical research services. It is also a co-construction unit of the National Resource Center for Genetically Engineered Mice recognized by the Ministry of Science and Technology.

 

Relying on its advanced animal model R&D platform, the company has built a globally leading resource library of genetically modified animal models, with nearly 30,000 genetically engineered mouse strains possessing independent intellectual property rights, providing comprehensive model resource support for preclinical research.

 

At present, GemPharmatech has established a full-process one-stop service platform for functional and efficacy analysis. Its business scope covers key disease areas including oncology, autoimmune diseases, metabolic and cardiovascular diseases, neurodegenerative diseases, respiratory infectious diseases and rare diseases. Services specifically include preclinical research such as target validation, pharmacodynamic evaluation and non-GLP safety evaluation. The company has completed over 300 IND application projects and maintains in-depth cooperation with more than 1,000 innovative pharmaceutical enterprises.

 

By further advancing the innovative application of gene-editing technologies and resource integration, GemPharmatech is dedicated to delivering high-quality animal models and technical services for life science research and the biomedical industry, and promoting the development of human health undertakings.